Aldo Del Col

416 total citations
7 papers, 267 citations indexed

About

Aldo Del Col is a scholar working on Hematology, Molecular Biology and Epidemiology. According to data from OpenAlex, Aldo Del Col has authored 7 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Molecular Biology and 1 paper in Epidemiology. Recurrent topics in Aldo Del Col's work include Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (3 papers) and Nuclear Structure and Function (3 papers). Aldo Del Col is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (3 papers) and Nuclear Structure and Function (3 papers). Aldo Del Col collaborates with scholars based in Canada, United States and Italy. Aldo Del Col's co-authors include Fiorenza Agosti, Stefano Bellentani, Giorgio Bedogni, Alessandro Sartório, G Mazzilli, Claudio Tiribelli, Heather J. Sutherland, Darrell White, Michaël Sébag and Jean‐Richard Saint‐Martin and has published in prestigious journals such as Blood and European Journal of Clinical Nutrition.

In The Last Decade

Aldo Del Col

6 papers receiving 265 citations

Peers

Aldo Del Col

EPIDE

MB

EDM

HEMAT

ONCOL

Norman Händel Germany

Hiroshi Isoda Japan

Lance L. Stein United States

H. Abid Tunisia

Magda D’Agostino Italy

B.R. Bacon United States

Cristiana Bianco Italy

Huma Arshad Cheema Pakistan

Francesca Capelli Italy

A. Jin Singapore

Norman Händel Germany

Aldo Del Col

139 ×1.1

EPIDE

92 ×0.9

MB

26 ×0.3

EDM

10 ×0.1

HEMAT

23 ×0.5

ONCOL

Citations per year, relative to Aldo Del Col Aldo Del Col (= 1×) peers Norman Händel

Countries citing papers authored by Aldo Del Col

Since Specialization

Citations

This map shows the geographic impact of Aldo Del Col's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aldo Del Col with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aldo Del Col more than expected).

Fields of papers citing papers by Aldo Del Col

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aldo Del Col. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aldo Del Col. The network helps show where Aldo Del Col may publish in the future.

Co-authorship network of co-authors of Aldo Del Col

This figure shows the co-authorship network connecting the top 25 collaborators of Aldo Del Col. A scholar is included among the top collaborators of Aldo Del Col based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aldo Del Col. Aldo Del Col is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Chen, Christine I., Heather J. Sutherland, Rami Kotb, et al.. (2018). Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 132(Supplement 1). 1993–1993. 3 indexed citations

2.

Bahlis, Nizar J., Heather J. Sutherland, Darrell White, et al.. (2018). Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 132(24). 2546–2554. 102 indexed citations

3.

White, Darrell, Nizar J. Bahlis, Christopher P. Venner, et al.. (2017). A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 130. 1861–1861. 4 indexed citations

4.

Bahlis, Nizar J., Heather J. Sutherland, Darrell White, et al.. (2017). Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM). Blood. 130. 3135–3135.

5.

Gasparetto, Cristina, Suzanne Lentzsch, Gary J. Schiller, et al.. (2017). A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs). Blood. 130. 3100–3100. 2 indexed citations

6.

Chen, Christine I., Heather J. Sutherland, Rami Kotb, et al.. (2017). Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure. Blood. 130. 3136–3136. 3 indexed citations

7.

Sartório, Alessandro, Aldo Del Col, Fiorenza Agosti, et al.. (2006). Predictors of non-alcoholic fatty liver disease in obese children. European Journal of Clinical Nutrition. 61(7). 877–883. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact